Prime Capital Investment Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.73M | Sell |
113,165
-3,312
| -3% | -$86.6K | 0.03% | 329 |
|
|
2026
Q1 | $3.27M | Sell |
116,477
-3,064
| -3% | -$81.6K | 0.04% | 288 |
|
|
2025
Q4 | $2.98M | Sell |
119,541
-3,747
| -3% | -$94.5K | 0.04% | 284 |
|
|
2025
Q3 | $3.14M | Sell |
123,288
-2,996
| -2% | -$73.9K | 0.04% | 273 |
|
|
2025
Q2 | $3.06M | Sell |
126,284
-37,464
| -23% | -$874K | 0.04% | 269 |
|
|
2025
Q1 | $4.15M | Buy |
163,748
+37,998
| +30% | +$994K | 0.05% | 251 |
|
|
2024
Q4 | $3.34M | Sell |
125,750
-44,564
| -26% | -$1.21M | 0.05% | 241 |
|
|
2024
Q3 | $4.93M | Sell |
170,314
-8,731
| -5% | -$255K | 0.07% | 192 |
|
|
2024
Q2 | $5.01M | Sell |
179,045
-52,320
| -23% | -$1.44M | 0.07% | 183 |
|
|
2024
Q1 | $6.42M | Buy |
231,365
+17,464
| +8% | +$485K | 0.09% | 171 |
|
|
2023
Q4 | $6.16M | Buy |
213,901
+60,547
| +39% | +$1.83M | 0.09% | 174 |
|
|
2023
Q3 | $5.09M | Sell |
153,354
-9,495
| -6% | -$336K | 0.1% | 155 |
|
|
2023
Q2 | $5.97M | Buy |
162,849
+32,408
| +25% | +$1.26M | 0.12% | 140 |
|
|
2023
Q1 | $5.32M | Sell |
130,441
-242,023
| -65% | -$10.5M | 0.22% | 94 |
|
|
2022
Q4 | $19.1M | Buy |
372,464
+87,161
| +31% | +$4.18M | 0.72% | 33 |
|
|
2022
Q3 | $12.5M | Buy |
285,303
+162,981
| +133% | +$7.92M | 0.72% | 27 |
|
|
2022
Q2 | $6.41M | Buy |
122,322
+7,439
| +6% | +$379K | 0.38% | 45 |
|
|
2022
Q1 | $6.78M | Sell |
114,883
-172
| -0.1% | -$8.92K | 0.38% | 48 |
|
|
2021
Q4 | $6.79M | Sell |
115,055
-22,260
| -16% | -$1.1M | 0.36% | 50 |
|
|
2021
Q3 | $5.91M | Buy |
137,315
+110,764
| +417% | +$4.91M | 0.37% | 49 |
|
|
2021
Q2 | $1.04M | Sell |
26,551
-9,757
| -27% | -$379K | 0.06% | 183 |
|
|
2021
Q1 | $1.31M | Sell |
36,308
-92,214
| -72% | -$3.27M | 0.1% | 152 |
|
|
2020
Q4 | $4.73M | Buy |
128,522
+63,134
| +97% | +$2.32M | 0.37% | 46 |
|
|
2020
Q3 | $2.28M | Buy |
65,388
+58,965
| +918% | +$2.07M | 0.19% | 98 |
|
|
2020
Q2 | $199K | Buy |
6,423
+253
| +4% | +$8.6K | 0.02% | 227 |
|
|
2020
Q1 | $191K | Sell |
6,170
-47,441
| -88% | -$1.62M | 0.02% | 195 |
|
|
2019
Q4 | $1.99M | Buy |
53,611
+50,156
| +1,452% | +$1.79M | 0.23% | 102 |
|
|
2019
Q3 | $118K | Buy |
3,455
+2,849
| +470% | +$104K | 0.02% | 233 |
|
|
2019
Q2 | $25K | Sell |
606
-1,090
| -64% | -$43.3K | ﹤0.01% | 284 |
|
|
2019
Q1 | $68K | Sell |
1,696
-11,576
| -87% | -$464K | 0.02% | 178 |
|
|
2018
Q4 | $550K | Buy |
13,272
+7,225
| +119% | +$300K | 0.2% | 83 |
|
|
2018
Q3 | $253K | Buy |
6,047
+5,968
| +7,554% | +$230K | 0.08% | 119 |
|
|
2018
Q2 | $3K | Hold |
79
| – | – | ﹤0.01% | 314 |
|
|
2018
Q1 | $3K | Hold |
79
| – | – | ﹤0.01% | 226 |
|
|
2017
Q4 | $3K | Buy |
+79
| New | +$2.69K | ﹤0.01% | 229 |
|
Other funds holding PFE
Prime Capital Investment Advisors's PFE Position: Q2 2026 in Review
Prime Capital Investment Advisors reduced its Pfizer (PFE) stake by 2.8% in Q2 2026, selling an estimated $86.6K and leaving 113,165 shares worth $2.73M. The position accounts for 0.03% of the portfolio, ranked #329.
Prime Capital Investment Advisors first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $19.1M in Q4 2022. 2,239 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Prime Capital Investment Advisors held 113,165 shares of Pfizer worth $2.73M as of Q2 2026.
- Prime Capital Investment Advisors sold 3,312 Pfizer shares in Q2 2026, an estimated $86.6K.
- Pfizer made up 0.03% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #329 holding.
- Prime Capital Investment Advisors first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Prime Capital Investment Advisors's Pfizer position peaked at $19.1M in Q4 2022.
- 2,239 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.